AstraZeneca PLC Ordinary Shares

About AstraZeneca PLC Ordinary Shares

AstraZeneca sells prescription medicines and earns revenue primarily through sales of its marketed drugs. Its portfolio spans Oncology, BioPharmaceuticals and Rare Disease; oncology is a significant growth contributor, with Q3 oncology sales up 17%, while mature medicines face generic pressure. Its products serve patients through healthcare systems, hospitals, clinics and pharmacies, with physicians and other healthcare professionals influencing treatment choices. The company also develops medicines through clinical trials and commercializes some products with partners, including Daiichi Sankyo on Enhertu. AstraZeneca reported Q3 profit attributable to owners of $3.12 billion, up from $2.53 billion a year earlier, and targets $80 billion in total revenue by 2030.

Notable Price Movement

1. Oct 26-30$186.658.84%

   AstraZeneca rose 1.06%, from $172.57 to $174.40, across the supplied endpoints. Trading was uneven: after closing at $172.06 on Monday, shares fell to $170.08 Tuesday and $169.51 Wednesday, then rebounded 2.9% Thursday to finish at the period high. The supplied company news was broadly positive: AstraZeneca beat Q3 earnings and revenue estimates, oncology sales grew 17%, and management reaffirmed its FY26 revenue and core-earnings guidance. Reports also highlighted 12 positive Phase 3 readouts and the EU approval of Enhertu for early breast cancer. The evidence does not establish which item drove Thursday’s reversal, and the news snippets do not map cleanly to the daily dates provided. The broader market context included pressure from questions about AI and oil prices.

   28 sources
2. Oct 19-23$171.493.68%

   AstraZeneca rose 3.55%, from $158.33 to $163.95, over the reported week. The stock first fell to $155.82 on October 13, then rallied to $162.03 on October 14 and a weekly high close of $166.68 on October 15, before easing to $163.95 by October 19. The midweek advance coincided with positive company-specific pipeline news: AstraZeneca reported positive Phase III results in eosinophilic esophagitis, while coverage also highlighted Tezspire data as strengthening its expansion case. The latter coverage explicitly linked the data to a 2.7% rise in AstraZeneca shares. The stock gave back some of its late-week advance, but remained above its October 12 close. The supplied evidence gives no market benchmark to separate broader-market effects.

   28 sources
3. Oct 12-16$165.413.90%

   AstraZeneca rose 1.15%, from $156.53 to $158.33, after climbing to $160.12 on Oct. 7 and giving back part of that advance over the following sessions. The sharpest reversal came on Oct. 8, when the close fell to $158.78 and trading volume reached 3.49 million shares; the stock then edged up on Oct. 9 before closing lower again on Oct. 12. Coverage during the period highlighted AstraZeneca’s AI drug-discovery partnership with insitro and its presentation at the American Society for Bone and Mineral Research meeting, while investors were also weighing valuation, patent pressure and pipeline execution. The supplied evidence does not establish that any of these items caused the daily price moves, and it provides no market benchmark for comparison.

   28 sources
4. Oct 5-9$159.201.47%

   AstraZeneca fell 3.41%, from $164.21 on September 29 to $158.61 on October 6. Shares declined through October 5, reaching $156.53, before rebounding 1.33% on October 6; that recovery did not erase the earlier losses. The supplied evidence does not identify a company-specific event that explains the week’s net decline or provide market-wide context to account for it. AstraZeneca-related headlines included the opening of its $1 billion Kendall Square R&D centre and the closing of a $2 billion strategic investment in Summit Therapeutics to support investigational ivonescimab, but the evidence does not establish that either announcement drove the share-price moves.

   28 sources
5. Sep 28 - Oct 2$156.905.81%

   AstraZeneca fell 4.17%, from $164.56 to $157.70. The shares reached $166.15 on September 28, then declined in each of the next three sessions, including a 1.17% drop to $164.21 on September 29. The supplied evidence does not identify a company-specific negative catalyst for the slide. AstraZeneca announced a $2 billion strategic equity investment in Summit Therapeutics and a cancer-drug collaboration involving Summit’s investigational ivonescimab; Daiichi Sankyo, AstraZeneca and Summit also agreed to study combinations with Datroway across solid tumors. Those developments add to the oncology pipeline but do not establish clinical outcomes. No broad-market performance data are supplied to explain the decline in context.

   18 sources
6. Sep 21-25$166.580.30%

   AZN gained 0.27% overall, from $162.89 to $163.33 across the supplied September 16–23 trading window. It rose to $166.14 on September 17, then traded nearly flat the following day; the advance resumed on September 21 and 22, taking the stock to $168.37. On September 23 it fell to $163.33, giving back nearly all of that rise. The supplied company-news coverage includes an EU approval for Trixeo in asthma, positive EU recommendations for Enhertu and Klygefa, and FDA priority reviews, but it provides no dates or evidence tying these announcements to the daily price moves. No market benchmark or broader market context is supplied to explain the reversal.

   28 sources
7. Sep 7-11$160.171.56%

   AstraZeneca fell $2.09, or 1.29%, from $162.13 to $160.04 over the observed week. The stock edged up to $162.47 on September 1, slipped to $161.63 the next day, then jumped $3.14 to $164.77 on September 3 before giving back $2.07 on September 4. It fell a further $2.66 on September 8, when volume rose to 5.15 million shares, above the roughly 2.4-3.3 million seen on most earlier sessions. The evidence does not establish which headlines drove individual sessions, but the news flow was mixed: positive survival data for the Amgen-AstraZeneca lung-cancer combination and positive COPD data for tozorakimab contrasted with a reported late-stage oncology trial miss.

   28 sources
8. Aug 31 - Sep 4$162.700.00%

   AstraZeneca rose $0.25, or 0.15%, from $164.52 to $164.77 over the week, but the path was volatile. The shares fell to $162.13 on Monday after declining from $164.52 on August 27, then edged up Tuesday before slipping to $161.63 on Wednesday. The main company-specific pressure was renewed concern around clinical setbacks, including full data from a failed cardiomyopathy trial that Stocktwits said drove AZN lower. The stock reversed sharply on Thursday, recovering the entire midweek decline, while positive pipeline coverage, including the Tagrisso-plus-Orpathys first-line NSCLC study, supported sentiment. No financial results or explicit weekly guidance change was supplied.

   28 sources
9. Aug 24-28$162.701.98%

   AstraZeneca fell 1.98% over the week, from $165.98 to $162.70. The stock initially gained, rising to $166.71 on Monday and $169.66 on Tuesday, before reversing sharply: it dropped to $166.27 on Wednesday, $164.52 on Thursday and $162.70 on Friday. The principal company-specific development was positive Phase 3 CROSSING data for Tezspire, the AstraZeneca-Amgen treatment for eosinophilic esophagitis, which met its co-primary and key secondary endpoints. That news did not prevent the subsequent three-day decline. The supplied evidence does not identify a negative AstraZeneca announcement or guidance change, so the late-week selling appears to have occurred without a clearly documented company-specific catalyst; broader market context is limited to a report of U.K. stocks closing 0.33% higher.

   23 sources
10. Aug 10-14$156.453.08%

    AstraZeneca rose $3.94, or 2.49%, from $157.97 to $161.91 across the supplied closes. Trading was volatile rather than steadily higher: the stock fell $2.35 on August 4 before surging $5.88 on August 5, then held near $161 through August 7 and added $0.49 on August 10. The clearest company-specific references in the supplied coverage were an earnings beat and reports that AstraZeneca ended takeover discussions with Bristol Myers Squibb after its share price dropped, although neither item is dated sufficiently to establish a direct causal link to each session. With no broader-market performance or other dated catalyst supplied, the week is best described as a rebound and consolidation without a fully explained company-specific driver.

    28 sources
11. Aug 3-7$161.424.85%

    AstraZeneca fell 9.78% over the week, from $172.48 to $155.62. The decline was concentrated on Monday, when the stock dropped to $157.97 on volume of 16.3 million shares, followed by a further fall to $155.62 on Tuesday. The main reported catalyst was news that AstraZeneca and Bristol Myers Squibb were in talks over a potential $400 billion combination, which appears to have heightened concerns about regulatory scrutiny and integration risks. The stock did not materially reverse the Monday selloff. No company financials were supplied for the period, so the move is best attributed to deal-related uncertainty rather than an earnings update.

    17 sources

Stories & Analysis

AstraZeneca: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 3d agoAstraZeneca (AZN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4d agoHealthcare Stocks Trade Higher: CDNA Gains 20%, REGN Adds 12%, PROF Climbs 10%, AZN Advances 7%RTTNews · 4d agoAstraZeneca Q3 Earnings Call HighlightsMarketBeat · 4d agoWeekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike DealsRTTNews · 5d agoFriday's ETF Movers: PPH, PSIBNK Invest · 5d agoPre-Markets Spooked on Questions Regarding AI, Oil PricesZacks · 5d agoAZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales GrowthZacks · 5d ago